Author

Judith Kemming

University of Freiburg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

Andreas VlachosiD· 1 shared Ariane LehmanniD· 1 shared Asma Y. AlrawashdehiD· 1 shared Bertram BengschiD· 1 shared Bismark AppiahiD· 1 shared Dietrich Alexander RuessiD· 1 shared Dominik von ElverfeldtiD· 1 shared Friederike Inga Nollmann· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andreas VlachosORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Philipp Hafner, Steffen Johannes Keller, Xun Chen, Asma Y. Alrawashdeh, Huda Jumaa, Friederike Inga Nollmann, Solène Besson, Judith Kemming, Oliver Gorka, Tonmoy Das, Bismark Appiah, Ariane Lehmann, Mujia Jenny Li, Petya Apostolova, Bertram Bengsch, , Dietrich Alexander Ruess

This study shows that dual SHP2/MEK inhibition in pancreatic cancer causes mitochondrial changes and ROS elevation, leading to a therapy-resistant state that can be targeted with GPX4 inhibition.

Signal Transduction and Targeted Therapy · Jan 16, 2026Peer-reviewedCancer Biology